US Patent No: 7,384,921

Number of patents in Portfolio can not be more than 2000

Polymorphic forms of 6-11 bicyclic ketolide derivatives

Stats

ALSO PUBLISHED AS: 20050203035
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are provided methods of producing the various polymorphic forms in pure form or in combination with one another. The present invention also provides pharmaceutical compositions and formulations comprising the polymorphic and amorphous forms and methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ENANTA PHARMACEUTICALS, INC.WATERTOWN, MA111

International Classification(s)

  • No International Classification to display

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gai, Yonghua North Grafton, MA 56 272
Li, Hui-Yin Hockessin, DE 27 101
Or, Yat Sun Watertown, MA 288 1583
Tang, Datong Malden, MA 43 293
Wang, Zhe Singapore 120206, SG 183 957
Xu, Guoyou Newton, MA 38 338

Cited Art

Patent Info (Count) # Cites Year
 
ABBVIE INC. (5)
5,780,605 6,9-bridged erythromycin derivatives 13 1997
5,922,683 Multicyclic erythromycin derivatives 30 1998
6,046,171 6,11-bridged erythromycin derivatives 25 1998
6,075,133 6-O-substituted antibacterial erythromycin ketolides and methods of making 17 1998
6,355,620 C-2 modified erythromycin derivatives 16 1999
 
ENANTA PHARMACEUTICALS, INC. (3)
6,878,691 6-11 bicyclic ketolide derivatives 23 2003
6,764,998 6,11-4C-bicyclic 9a-azalide derivatives 14 2003
2005/0009,761 Bridged macrocyclic compounds and processes for the preparation thereof 13 2004
 
ABBOTT LABORATORIES (2)
6,274,715 Tricyclic erythromycin derivatives 25 1997
6,054,435 6-O-substituted macrolides having antibacterial activity 21 1999
 
APOTEX TECHNOLOGIES INC. (1)
6,245,903 Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof 24 1999
 
NOVADEL PHARMA INC. (1)
2003/0082,107 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer 10 2002
 
Pharmacin Corporation (1)
5,118,799 Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate 6 1989
 
Other [Check patent profile for assignment information] (2)
2005/0009,763 6,11-4-Carbon bridged erythromycin derivatives 8 2004
2005/0014,707 6,11-4C-bicyclic 9a-azalide derivatives 10 2004

Patent Citation Ranking

  • No Patent Citation Ranking to display

Forward Cites

Patent Info (Count) # Cites Year
 
ENANTA PHARMACEUTICALS, INC. (3)
8,273,720 6,11-bicyclolides: bridged biaryl macrolide derivatives 0 2009
8,354,383 6,11-bridged biaryl macrolides 0 2009
8,383,785 Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides 0 2009
 
SANOFI (1)
8,383,146 Compositions for oral adminstration of active principles requiring masking of taste 0 2012

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 10, 2015
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 10, 2019
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00